Literature DB >> 23616545

Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Carlos Cepeda1, Laurie Galvan, Sandra M Holley, Shilpa P Rao, Véronique M André, Elian P Botelho, Jane Y Chen, Joseph B Watson, Karl Deisseroth, Michael S Levine.   

Abstract

In Huntington's disease (HD) mouse models, spontaneous inhibitory synaptic activity is enhanced in a subpopulation of medium-sized spiny neurons (MSNs), which could dampen striatal output. We examined the potential source(s) of increased inhibition using electrophysiological and optogenetic methods to assess feedback and feedforward inhibition in two transgenic mouse models of HD. Single whole-cell patch-clamp recordings demonstrated that increased GABA synaptic activity impinges principally on indirect pathway MSNs. Dual patch recordings between MSNs demonstrated reduced connectivity between MSNs in HD mice. However, while connectivity was strictly unidirectional in controls, in HD mice bidirectional connectivity occurred. Other sources of increased GABA activity in MSNs also were identified. Dual patch recordings from fast spiking (FS) interneuron-MSN pairs demonstrated greater but variable amplitude responses in MSNs. In agreement, selective optogenetic stimulation of parvalbumin-expressing, FS interneurons induced significantly larger amplitude MSN responses in HD compared with control mice. While there were no differences in responses of MSNs evoked by activating single persistent low-threshold spiking (PLTS) interneurons in recorded pairs, these interneurons fired more action potentials in both HD models, providing another source for increased frequency of spontaneous GABA synaptic activity in MSNs. Selective optogenetic stimulation of somatostatin-expressing, PLTS interneurons did not reveal any significant differences in responses of MSNs in HD mice. These findings provide strong evidence that both feedforward and to a lesser extent feedback inhibition to MSNs in HD can potentially be sources for the increased GABA synaptic activity of indirect pathway MSNs.

Entities:  

Mesh:

Year:  2013        PMID: 23616545      PMCID: PMC3686572          DOI: 10.1523/JNEUROSCI.2137-12.2013

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  64 in total

1.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.

Authors:  G J Klapstein; R S Fisher; H Zanjani; C Cepeda; E S Jokel; M F Chesselet; M S Levine
Journal:  J Neurophysiol       Date:  2001-12       Impact factor: 2.714

2.  Selective inhibition of striatal fast-spiking interneurons causes dyskinesias.

Authors:  Aryn H Gittis; Daniel K Leventhal; Benjamin A Fensterheim; Jeffrey R Pettibone; Joshua D Berke; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

Review 3.  Physiology and pharmacology of striatal neurons.

Authors:  Anatol C Kreitzer
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

4.  Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.

Authors:  G A Laforet; E Sapp; K Chase; C McIntyre; F M Boyce; M Campbell; B A Cadigan; L Warzecki; D A Tagle; P H Reddy; C Cepeda; C R Calvert; E S Jokel; G J Klapstein; M A Ariano; M S Levine; M DiFiglia; N Aronin
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

5.  Distinct roles of GABAergic interneurons in the regulation of striatal output pathways.

Authors:  Aryn H Gittis; Alexandra B Nelson; Myo T Thwin; Jorge J Palop; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

Review 6.  GABAergic circuits of the striatum.

Authors:  H Kita
Journal:  Prog Brain Res       Date:  1993       Impact factor: 2.453

7.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease.

Authors:  Michael A Johnson; Vignesh Rajan; Charles E Miller; R Mark Wightman
Journal:  J Neurochem       Date:  2006-03-29       Impact factor: 5.372

8.  Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.

Authors:  R L Albin; A Reiner; K D Anderson; L S Dure; B Handelin; R Balfour; W O Whetsell; J B Penney; A B Young
Journal:  Ann Neurol       Date:  1992-04       Impact factor: 10.422

9.  Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease.

Authors:  Stefano Taverna; Ema Ilijic; D James Surmeier
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

10.  Dopaminergic modulation of axon collaterals interconnecting spiny neurons of the rat striatum.

Authors:  Jaime N Guzmán; Adán Hernández; Elvira Galarraga; Dagoberto Tapia; Antonio Laville; Ramiro Vergara; Jorge Aceves; José Bargas
Journal:  J Neurosci       Date:  2003-10-01       Impact factor: 6.167

View more
  60 in total

Review 1.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

2.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

3.  Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells.

Authors:  S E Dougherty; J J Hollimon; L J McMeekin; A S Bohannon; A B West; M Lesort; J J Hablitz; R M Cowell
Journal:  Neurobiol Dis       Date:  2013-10-11       Impact factor: 5.996

4.  Loss-of-Huntingtin in Medial and Lateral Ganglionic Lineages Differentially Disrupts Regional Interneuron and Projection Neuron Subtypes and Promotes Huntington's Disease-Associated Behavioral, Cellular, and Pathological Hallmarks.

Authors:  Mark F Mehler; Jenna R Petronglo; Eduardo E Arteaga-Bracho; Maria E Gulinello; Michael L Winchester; Nandini Pichamoorthy; Stephen K Young; Christopher D DeJesus; Hifza Ishtiaq; Solen Gokhan; Aldrin E Molero
Journal:  J Neurosci       Date:  2019-01-09       Impact factor: 6.167

Review 5.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

6.  Parvalbumin Interneurons Modulate Striatal Output and Enhance Performance during Associative Learning.

Authors:  Kwang Lee; Sandra M Holley; Justin L Shobe; Natalie C Chong; Carlos Cepeda; Michael S Levine; Sotiris C Masmanidis
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

Review 7.  Unravelling and Exploiting Astrocyte Dysfunction in Huntington's Disease.

Authors:  Baljit S Khakh; Vahri Beaumont; Roger Cachope; Ignacio Munoz-Sanjuan; Steven A Goldman; Rosemarie Grantyn
Journal:  Trends Neurosci       Date:  2017-05-31       Impact factor: 13.837

8.  Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Authors:  Sandra M Holley; Laurie Galvan; Talia Kamdjou; Carlos Cepeda; Michael S Levine
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

9.  Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.

Authors:  Alipi V Naydenov; Marja D Sepers; Katie Swinney; Lynn A Raymond; Richard D Palmiter; Nephi Stella
Journal:  Neurobiol Dis       Date:  2014-08-15       Impact factor: 5.996

10.  A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.

Authors:  Danielle A Simmons; Nadia P Belichenko; Tao Yang; Christina Condon; Marie Monbureau; Mehrdad Shamloo; Deqiang Jing; Stephen M Massa; Frank M Longo
Journal:  J Neurosci       Date:  2013-11-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.